PLENARY PANEL DISCUSSION
TUESDAY, AUGUST 22
11:30 am PLENARY PANEL DISCUSSION: Policy and Practice Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care
PANEL MODERATOR:
Daryl Pritchard, PhD, Senior Vice President, Science Policy, Personalized Medicine Coalition
Many oncology patients who are eligible to receive high-value personalized treatments do not. Despite a lengthy history of targeted treatment availability in advanced non-small cell lung cancer (aNSCLC), a recent study found that 644 of every 1,000 newly diagnosed aNSCLC patients (64.4%) did not receive a personalized treatment due to clinical practice gaps in the delivery of precision oncology.
- What are the clinical practice and policy challenges related to diagnostic testing and the delivery of appropriate targeted therapies leading to a failure of patients to receive precision oncology strategies?
- What impact does each clinical practice gap have on the population-level delivery of precision oncology?
- How can we optimize biomarker testing and treatment decision-making to help best address clinical practice gaps?
- What policies and practices can help assure optimal and equitable delivery of appropriate high-value personalized medicines?
PANELISTS:
Robert H. Dumanois, Director, Reimbursement Strategy, Thermo Fisher Scientific
Anthony N. Sireci, MD, MSc, Senior Vice President, Clinical Biomarkers & Diagnostics Division, Loxo Oncology, Inc.
Apostolia-Maria Tsimberidou, MD, PhD, FASCO, FAASS, Professor of Medicine, Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center